NovoCure/$NVCR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About NovoCure
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Ticker
$NVCR
Sector
Trading on
Industry
Health Care Equipment & Supplies
Headquarters
Baar, Switzerland
Employees
1,488
ISIN
JE00BYSS4X48
Website
NovoCure Metrics
BasicAdvanced
$2.2B
-
-$1.51
0.65
-
Price and volume
Market cap
$2.2B
Beta
0.65
52-week high
$34.13
52-week low
$14.17
Average daily volume
947K
Financial strength
Current ratio
1.465
Quick ratio
1.409
Long term debt to equity
38.06
Total debt to equity
192.489
Interest coverage (TTM)
-15.84%
Management effectiveness
Return on assets (TTM)
-8.64%
Return on equity (TTM)
-45.52%
Valuation
Price to revenue (TTM)
3.388
Price to book
5.98
Price to tangible book (TTM)
5.98
Price to free cash flow (TTM)
-29.201
Growth
Revenue change (TTM)
18.27%
Earnings per share change (TTM)
-16.51%
3-year revenue growth (CAGR)
4.95%
3-year earnings per share growth (CAGR)
38.67%
What the Analysts think about NovoCure
Analyst ratings (Buy, Hold, Sell) for NovoCure stock.
NovoCure Financial Performance
Revenues and expenses
NovoCure Earnings Performance
Company profitability
NovoCure News
AllArticlesVideos
NovoCure: Loading Up On Growth Catalysts
Seeking Alpha·6 days ago
NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025
Benzinga·1 month ago
Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for NovoCure stock?
NovoCure (NVCR) has a market cap of $2.2B as of May 30, 2025.
What is the P/E ratio for NovoCure stock?
The price to earnings (P/E) ratio for NovoCure (NVCR) stock is 0 as of May 30, 2025.
Does NovoCure stock pay dividends?
No, NovoCure (NVCR) stock does not pay dividends to its shareholders as of May 30, 2025.
When is the next NovoCure dividend payment date?
NovoCure (NVCR) stock does not pay dividends to its shareholders.
What is the beta indicator for NovoCure?
NovoCure (NVCR) has a beta rating of 0.65. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.